Free for download in the new issue of Behavioural Pharmacology: a fascinating paper by Pham et al., showing how kappa opioid receptors in the nucleus accumbens and VTA contribute to the aversive properties of nicotine.
https://t.co/pxsy7E6WRr
Free download in our 2022 Special Issue on Cannabinoids: an innovative review by @CassieMoorePhD et al. on translational models of cannabinoid vapor exposure. All you need to know!
https://t.co/eD3c6A3iD5
Our Special Issue on Cannabinoids is here! Check out the exciting papers on the involvement of cannabinoids in addiction, pain, anxiety and learning - featuring four reviews and seven empirical papers:
https://t.co/sekmWqhNZW
Registration is now OPEN for our 2022 workshop, 'Spanning the spectrum of social behavior: towards more translationally relevant animal models.' Spread the word! See you in Rome! Link: https://t.co/NcfLKDvEKM
New to cannabinoid vape research and trying to figure out optimal parameters for your studies?
💨🐀
Check out our review in the current issue on cannabinoids in @BehaviourPharma We cover methodological details of vaping used across different studies and labs. @CassieMoorePhD
Our review about TRPV1 blockers in psychiatric disorders is available now (free download). Clinical, preclinical , pharmacology & future directions.
FB is welcome!
Are you working on synaptopathies or psychedelic drugs? We announce two special issues of Behavioural Pharmacology on these topics!
https://t.co/etEvV3sXhw
Free for download in the latest issue of Behavioural Pharmacology: an innovative review by Iglesias et al. on the potential use of TRPV1 blockers for the treatment of anxiety, depression, addiction and neurodevelopmental disorders.
https://t.co/E1AEDQBeKX
The first issue in 2022 of Behavioural Pharmacology is out! Have a look at exciting papers on pain, anxiety, learning and alcohol use here:
https://t.co/CQZPMLlssV
Free for download in the current issue of Behavioural Pharmacology: an exciting study by Galal et al. on how the PPAR-alpha agonist fenofibrate reduces side effects of olanzapine treatment, without changing its antipsychotic effects.
https://t.co/K6yzYmOSPF
We have a new issue of Behavioural Pharmacology out! Have a look at the contents - very nice work on pain, antidepressants, antipsychotics and neuroinflammation - here:
https://t.co/sekmWqhNZW
@RyanMcPickle Check out the @BehaviourPharma review from @CassieMoorePhD and I that covers the different variables used in vape research on cannabinoids including puff durations, intervals and session lengths.
https://t.co/xid1nw6Jgs
Nobel Prize for David Julius / TRPV1 !! @DJuliusSF @NobelPrize#TRPV1
Taking the opportunity to share our recent review on the pharmacology of brain TRPV1 & psychiatric disorders!
@BehaviourPharma
https://t.co/1YESQN5EUr
Free for download in the new issue of Behavioural Pharmacology: a fascinating study by @S_Grella et al., showing how hippocampal norepinephrine can work as a switch between memory retrieval and updating.
https://t.co/oZE1DeNf0B
Out now: the new issue of Behavioural Pharmacology! It features a set of exciting studies on learning & memory, depression, pain and social behaviour. Have a look here:
https://t.co/sekmWqhNZW
PhD publication #2 just landed in @BehaviourPharma ☺️🎉 where we found that a high, escalating dose of morphine during conditioning failed to elicit #placebo analgesia in rats with neuropathic pain. Thanks @LNSFSydney. Check it out 👇
https://t.co/wpWIEF2prV
@OpenAcademics
More work from the growing thesis of PhD student @Damboorman …. @BehaviourPharma Escalating morphine dosage fails to elicit conditioned... : Behavioural Pharmacology https://t.co/vatlLZnqdK
Free for download in our latest issue: a fascinating study by Vilhena et al., demonstrating that treatment with the phosphodieasterase 4 inhibitor roflumilast prevents behavioural and cellular consequences of cerebral ischemia
https://t.co/CEvkv6NjP0